In this article, we will discuss Olaparib (Clinical Trials Experience-2). So, let’s get started.
- Maintenance Treatment of Recurrent Ovarian Cancer
- The safety of Olaparib for the maintenance treatment of patients with platinum sensitive gBRCAm ovarian cancer was investigated in SOLO-2. This study was a placebo-controlled, double-blind study in which 294 patients received either Olaparib 300 mg (2 x 150 mg tablets) twice daily (n=195) or placebo tablets twice daily (n=99) until disease progression or unacceptable toxicity. The median duration of study treatment was 19.4 months for patients who received Olaparib and 5.6 months for patients who received placebo.